Adgero Biopharmaceuticals

Adgero Biopharmaceuticals is a biopharmaceutical company focused on developing innovative photodynamic therapy (PDT) for the treatment of serious oncology indications, particularly rare and unmet medical needs in cancer. Founded in 2007 and headquartered in Pittstown, New Jersey, Adgero's lead product, REM-001 Therapy, utilizes a combination of laser light, a light delivery device, and a drug to target cutaneous metastatic cancers. The therapy has shown promising safety and efficacy results in Phase 2/3 clinical trials, specifically for patients with cutaneous metastatic breast cancer who have not responded to radiation therapy. The company's ongoing research aims to leverage existing data and complete further clinical trials to facilitate potential regulatory approval for REM-001, thereby expanding treatment options for patients suffering from serious skin cancers.